The FDA has approved Kedrion Biopharma’s Qivigy, a 10% IV immunoglobulin therapy, for treating adults who have primary ...

The guideline incorporates the latest advice on diagnosis and treatment, lowering proteinuria targets, and integrating new ...

Kelley L. Julian, PharmD, BCOP, discusses optimizing MM care, addressing barriers in access to intravenous immunoglobulin and innovative therapies at Huntsman Cancer Institute.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and ...

Advances in our understanding of the pathogenesis of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus have led to the emergence of immunoglobulin-based therapy as a ...

Administration of high-dose IVIg rapidly increases platelet numbers in individuals with the platelet autoimmune disease ITP. Although also of benefit in other autoimmune disorders, including ...

In a recent study published in The Journal of Allergy and Clinical Immunology, researchers in New Zealand gathered evidence to show that selective immunoglobulin A deficiency (sIgAD) is an understated ...

Medically reviewed by Jurairat J. Molina, MD Key Takeawyas High IgE levels can be associated with various conditions, ...

Antigen-driven selection has been implicated in the pathogenesis of monoclonal gammopathies. Patients with Gaucher’s disease have an increased risk of monoclonal gammopathies. Here we show that the ...